Albireo Pharma

Albireo Pharma is a biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company's primary product candidate, A4250, is used for the treatment of progressive familial intrahepatic cholestasis (PFIC), pruritus associated with PFIC, Alagille syndrome and biliary atresia. The company's product candidates in addition to A4250 include elobixibat, which is approved in Japan for the treatment of chronic constipation, and A3384, which is a product candidate to treat bile acid malabsorption.
  • TickerALBO
  • ISINUS01345P1066
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Wedbush Research

Wedbush Morning Call - Jul 13 2020 6:44AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 29 2020 6:40AM

Wedbush Research

Wedbush Morning Call - Jul 13 2020 6:44AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 29 2020 6:40AM

ResearchPool Subscriptions

Get the most out of your insights

Get in touch